Preclinical evidence that targeting the insulin-like growth factor receptor (IGF-IR) is effective in cancer treatment has been accumulating for almost two decades. Efforts to develop drugs began in the late 1990s, and initial data from clinical trials were reported in 2006. The biological rationale for IGF-IR targeting has potential relevance to many tumor types, and early results have justified expanded programs to evaluate IGF-IR-targeting agents in many areas of clinical need. More than two dozen drug candidates have been developed and clinical trials are underway for at least 12 of these. Early clinical trials reveal an acceptable safety profile together with pharmacodynamic evidence that the receptor can be successfully targeted. It is premature to draw conclusions regarding efficacy, but well-documented instances of single-agent activity were noted during phase I evaluations, and recent evidence from a phase II study suggests that co-administration of an anti-IGF-IR antibody with chemotherapy for non-small-cell lung cancer improves objective response rate and progression-free survival. With more than 70 trials involving a variety of drug candidates underway, the IGF-IR is becoming one of the most intensively investigated molecular targets in oncology. Early results justify the continuation of ongoing research across a broad range of cancer indications.
Introduction
Research on insulin-like growth factors (IGFs) and their receptors in cancer biology has been ongoing for over 20 years (Myal et al., 1984; Pollak et al., 1987; Arteaga et al., 1989) . Model systems provided evidence for important roles in neoplasia. Examples include genetic alterations that reduce ligand levels (Pollak et al., , 2004 Baserga et al., 2003; Majeed et al., 2005; Hartog et al., 2007; Sachdev and Yee, 2007; Samani et al., 2007; Chitnis et al., 2008; Weroha and Haluska, 2008; Yuen and Macaulay, 2008; Pollak, 2008a) as well as knockdown methods (Wu et al., 2003) . One important theme that emerged from this work was the notion that multiple oncogenes require the presence of the insulinlike growth factor receptor (IGF-IR) to achieve cellular transformation (Sell et al., 1993; Martin et al., 2006) ; another was that that IGF-I signaling confers resistance to many antineoplastic therapies (Wiseman et al., 1993; Lu et al., 2001) . Interest in IGF-IR targeting increased with the publication of evidence linking IGF-I signaling with the onset of neoplasia. Examples include evidence for associations between circulating IGF-I and cancer risk (Chan et al., 1998) , between IGF-I and mammographic breast density (Diorio et al., 2005) , between growth rate in adolescence (which is IGF-I mediated) and cancer risk (Ahlgren et al., 2004) , and the observation that IGF-II overexpression was among the most common molecular derangements in colorectal cancer (Zhang et al., 1997) .
Earlier review articles (Baserga et al., 2003; Pollak et al., 2004; Hartog et al., 2007; Sachdev and Yee, 2007; Samani et al., 2007; Chitnis et al., 2008; Weroha and Haluska, 2008; Yuen and Macaulay, 2008; Pollak, 2008a) have summarized IGF-IR biology, its relevance to neoplasia and the preclinical evaluation of drug candidates targeting the IGF-IR. Recent studies have provided further evidence that IGF-IR inhibition can be useful in attenuating the malignant behavior of cancers in which KRAS (Klinakis et al., 2009) or EGF receptor family members (Buck et al., 2008; Huang et al., 2009) play important roles in pathophysiology.
Close to 30 drug candidates targeting the IGF-IR are being investigated (Baserga et al., 2003; Pollak et al., 2004; Yee, 2006; Hartog et al., 2007; Sachdev and Yee, 2007; Samani et al., 2007; Tao et al., 2007; Chitnis et al., 2008; Feng and Dimitrov, 2008; Rodon et al., 2008; Yuen and Macaulay, 2008; Pollak, 2008a, b) . Here, we focus specifically on the available clinical trial and translational research data concerning 12 of these compounds currently in clinical trials. The large number of trials planned and in progress provide important opportunities for the incorporation of 'companion' studies that will provide serum and tissue samples for analysis of patterns of gene expression, activation of signaling pathways, circulating growth factor levels, and genetic variation in the germline and within neoplastic tissue that may predict response.
Clinical trials of IGF-IR inhibitors

A12
Phase I trials evaluating the human anti-IGF-IR IgG1 antibody, A12 (cixutumumab, Imclone, New York, NY, USA), given weekly or every 2 weeks (q2weeks) at doses of 3-27 mg/kg are being conducted in patients with refractory tumors (NCT00785538, NCT00785941) (Higano et al., 2007; Rothenberg et al., 2007) . Toxicity reported includes grade 3 hyperglycemia and grade 2 anemia, psoriasis, hyperglycemia and infusion-related reaction (Table 1) . Mean half-lives of up to 211 h at 15 mg/kg/q2weeks dosing have been reported. IGF-I elevations post-A12 dosing were also observed. No objective responses have been yet seen but two disease stabilizations >9 months (one male breast cancer, one hepatocellular cancer) were reported on weekly dosing. This initial favorable profile supported the initiation of a large clinical testing program in 18 trials of A12 alone or in combination with other agents (Table 2) .
AMG-479
The safety of the human anti-IGF-IR IgG1 antibody, AMG-479 (Amgen, Thousand Oaks, CA, USA), at doses of 1-20 mg/kg/q2weeks was investigated in a phase I study . Grade 3 thrombocytopenia was considered dose limiting at 20 mg/kg. Additional grade 3/4 non-hematological toxicities were observed in two patients; however, no hyperglycemia greater than grade 2 was reported. Anti-AMG-479 antibodies were detected in one patient and one additional patient had an infusion reaction (grade 2). AMG-479 exhibited dose-linear pharmacokinetics reaching steady state at cycle 3 with a mean terminal half-life of 7-11 days. Pharmacodynamic studies showed a trend to dose-proportional receptor occupancy in neutrophils and elevations of serum IGF-I, and IGFbinding protein-3 (IGFBP-3). Well-documented tumor responses in patients with Ewing's sarcoma and neuroendocrine carcinoma (one each) were reported . Furthermore, early data from a phase Ib combination study of AMG-479 with either panitumumab or gemcitabine have been reported (NCT00788957, NCT00630552) (Sarantopoulos et al., 2008) . Patients with advanced solid tumors received panitumumab (6 mg/kg/q2weeks) or gemcitabine (1000 mg/m 2 on days 1, 8 and 15 every 4 weeks (q4weeks)) in combination with AMG-479 at 6 or 
AVE1642
Two phase I studies of the anti-IGF-IR antibody, AVE1642 (Sanofi-Aventis, Paris, France), were reported. A dose escalation (3-12 mg/kg/q3weeks) was conducted in patients with refractory multiple myeloma (Moreau et al., 2007) . AVE1642 was well tolerated in 14 patients dosed for a median of three cycles. Two grade 3 hyperglycemias were observed in diabetic patients. No hypersensitivity or anti-drug antibodies were detected. In the second study, AVE1642 (3-12 mg/kg) was administered every 3 weeks (q3weeks) as single agent at cycle 1 and then combined with docetaxel (75 mg/m 2 ) at cycle 2 and beyond in patients with advanced solid tumors (Tolcher et al., 2008) . No dose-limiting toxicity (DLT) has been yet reported. Grade 1/2 toxicity included hyperglycemia (one case) and hypersensitivity reactions (two cases). AVE1642 half-life was estimated to be approximately 9 days. AXL1717 AXL1717 (Axelar, Stockholm, Sweden) is a smallmolecule IGF-IR inhibitor investigated in phase I trials. Structurally, AXL1717 is based on a cyclolignan derivative picropodophyllin that seems to have some selectivity for the IGF-IR versus other tyrosine kinases, including the insulin receptor (IR) (Girnita et al., 2004) . No clinical information has yet been released.
BIIB022
BIIB022 (Biogen, Cambridge, MA, USA) is a human anti-IGF-IR non-glycosylated IgG4 antibody. A phase I dose-escalation study of BIIB022 given q3weeks to patients with relapsed or refractory solid tumors is currently underway (NCT00555724).
BMS-754807
BMS-754807 (Bristol-Myers, New York, NY, USA) is a small molecule antagonist of the IGF-IR administered orally. A multiple-dose study of the safety of BMS-754807 in patients with advanced solid tumors (NCT00569036) has been initiated with a starting dose of 4 mg/day.
CP-751,871
CP-751,871 (figitumumab, Pfizer New York, NY, USA) is a human anti-IGF-IR IgG2 antibody. Over 1000 patients have participated in CP-751,871 trials. The firstin-human study was a dose escalation (0.025-20 mg/kg/ q4weeks) in patients with refractory myeloma . A total of 47 patients were enrolled and no DLT was observed. Grade 3 events included hyperglycemia and anemia (one case each). The effective half-life of CP-751,871 at the 20 mg/kg dose was estimated to be 
Abbreviations: ACC, adrenocortical carcinoma; ALL, acute lymphocytic leukemia; BC, breast cancer; CML, chronic myeloid leukemia; CRC, colorectal carcinoma; H&N, head and neck; HCC, hepatocellular carcinoma; IGF-IR, insulin-like growth factor type I receptor; NSCLC, non-small-cell lung cancer.
Clinical experience with IGF-IR inhibitors A Gualberto and M Pollak 20 days. Several pharmacodynamic end points were investigated. Granulocyte IGF-IR expression decreased in a dose-dependent manner together with substantial dose-dependent increases in circulating IGF-I, with >10-fold elevations from baseline at the 20 mg/kg dose (up to 1200 ng/ml), and more modest increases in IGFBP-3 (two-to three-fold). Patients with suboptimal response to CP-751,871 alone were eligible to receive CP-751,871 in combination with dexamethasone (3 Â 40 mg q4weeks) or rapamycin (2 mg/day daily). A total of nine responses by European Group for Blood and Marrow Transplant criteria were noted in 27 patients receiving CP-751,871 and dexamethasone, including two patients progressing on dexamethasone regimens at study entry.
Further phase I experience involved a dose escalation of CP-751,871 (3-20 mg/kg/q3weeks) in patients with refractory solid tumors NCT00474760) . In addition, two extension cohorts at the 20 mg/kg dose, one in adrenocortical carcinoma (ACC) patients (N ¼ 21) and another in patients with sarcoma (N ¼ 26), were conducted (Olmos et al., 2007 (Olmos et al., , 2008 Postel-Vinay et al., 2008) . In the dose-escalation portion of the study, 110 treatment cycles were administered to 24 patients with no DLTs observed. Grade 3 events included elevated g-glutamyltransferase, fatigue and arthralgia. Greater than doubling of baseline growth hormone (GH) levels was observed, indicating systemic inhibition of the IGF-IR with the loss of regulatory feedback at the pituitary (discussed below), as well as modest increases in fasting glucose (Gualberto et al., 2008b) . Pharmacokinetic analysis revealed a dosedependent increase in CP-751,871 concentrations with an approximately twofold accumulation on repeated dosing. No objective responses were observed but two patients experienced >1 year disease stabilization. Adverse events in sarcoma patients included one grade 4 uric acid elevation and one grade 3 deep-vein thrombosis. In ACC patients, several grade 3 elevations of liver function tests were observed. A complete response was observed in a patient with Ewing's sarcoma. Stable disease was seen in 12 of 20 evaluable sarcoma and 9 of 13 ACC patients. An additional phase Ib study investigated the safety of CP-751,871 (0.1-20 mg/kg) in combination with docetaxel (75 mg/ m 2 ) in 27 advanced disease patients (Attard et al., 2006) . Grade 3/4 toxicities reported were attributed to docetaxel and included neutropenia (n ¼ 18) and diarrhea (n ¼ 3). Of 20 hormone-resistant prostate cancer patients treated, eight had confirmed prostate-specific antigen responses. This study also included the enumeration and assessment of circulating tumor cells expressing the IGF-IR (IGF-IR CTCs) (De Bono et al., 2007) . IGF-IR CTCs were detectable in 50% of hormone-resistant prostate cancer patients and their decline post treatment seemed to be associated with prostate-specific antigen response. Furthermore, a simultaneous decrease in total CTC counts was observed in CP-751,871-treated patients, suggesting that the IGF-IR may be required for CTC migration from tumor sites, their survival in the blood stream or homing at new metastatic sites.
Safety and efficacy in combination with paclitaxel and carboplatin were investigated in a phase Ib/II study of CP-751,871 given at 0.05-20 mg/kg/q3weeks (NCT00147537) Karp et al., 2009) . A total of 42 patients were enrolled in the phase Ib portion with no DLTs observed. Grade 3 events included g-glutamyltransferase elevation, diarrhea, asthenia and hyperglycemia (one case each). Sustained decreases in circulating cleaved soluble IGF-IR to undetectable levels for the complete dosing period, as well as increases in the plasma concentrations of free IGF-I (5-to 10-fold) and IGFBP-3 (2-to 3-fold), were observed at doses X6 mg/kg. In all, 15 objective responses were observed in the phase Ib portion of the study, including two complete responses in non-smallcell lung cancer (NSCLC) and ovarian carcinoma patients. The phase II portion of the study was a randomization of treatment-naive NSCLC patients to paclitaxel, carboplatin, and CP-751,871 or to paclitaxel/ carboplatin alone. In total, 10-20 mg/kg/q3weeks CP-751,871 dosing were investigated (N ¼ 151) . A total of 42 and 54% of patients receiving, respectively, chemotherapy and chemotherapy with CP-751,871 had objective responses. Analyses by dose and histology revealed an apparent dose-response relationship for patients with squamous cell and adenocarcinoma histologies, with response rates for chemotherapy alone or with CP-751,871 at 10 and 20 mg/kg, respectively, of 33, 43 and 62%. The combination was well tolerated with a low incidence of treatment-related grade 3/4 toxicities. Grade 3/4 hyperglycemia was seen in 15% of patients receiving paclitaxel/carboplatin and CP-751,871 and 8% of patients receiving chemotherapy alone. On the basis of these results, phase III studies are being conducted in treatment-naive and refractory NSCLC (NCT00673049, NCT00596830) (Gualberto and Karp, 2009) .
Additional phase II studies include testing of CP-751,871 as first line treatment for hormone-resistant prostate cancer in combination with docetaxel and prednisone (NCT00313781), and a combination with exemestane in advanced estrogen receptor-positive breast cancer (NCT00372996). Initial data indicate that these combinations are well tolerated Ryan et al., 2008) .
MK0646
The safety of the anti-IGF-IR antibody, MK0646 (Merck, Whitehouse Station, NJ, USA), was investigated in two phase I studies (NCT00282737, NCT00701103). In the first, 48 patients with IGF-IRexpressing tumors were given MK0646 weekly at 1.25-20 mg/kg (Atzori et al., 2008) . Sequential skin and tumor biopsies were collected and fluorodeoxyglucose positron emission tomography carried out before and on treatment. A DLT of grade 3 thrombocytopenia was noted at 5.0 mg/kg. Pharmacokinetics indicated dose-proportionality and a mean terminal half-life of approximately 4 days. Decreases in tumor IGF-IR levels and downstream signaling, and increases in circulating Clinical experience with IGF-IR inhibitors A Gualberto and M Pollak IGF-I levels (twofold) were documented. Fluorodeoxyglucose positron emission tomography metabolic responses occurred in three patients but no objective responses were observed. In the second study, 29 patients were enrolled in three stages (NCT00635778) (Hidalgo et al., 2008) . In stages 1 and 2, patients were treated with loading doses of MK0646 (2.5-20 mg/kg) followed by maintenance doses (2.5-15 mg/kg/q2weeks). In stage three (not completed at the time of the report), patients are treated with a 15 mg/kg loading dose and 10 mg/kg/q2weeks maintenance dose. A DLT of grade 4 thrombocytopenia was observed at the 15 mg/kg loading dose in the 5 mg/kg maintenance cohort. Grade 3 toxicity included thrombocytopenia, gastrointestinal bleeding, pneumonitis and increase in the liver function tests. Pharmacokinetic analysis suggested a terminal half-life of approximately 100 h (range, 54-296). Although no objective responses were observed, two patients have had disease stabilization for >1 year. MK0646 is being further evaluated in a phase II/III study in combination with cetuximab and irinotecan in metastatic colorectal cancer that progressed on prior irinotecan therapy (NCT00614393) (Tabernero, 2008) .
OSI-906
OSI-906 (OSI Pharmaceuticals, Melville, NY, USA) is an oral small molecular weight tyrosine kinase inhibitor of the IGF-IR. Two phase I trials are underway investigating continuous (NCT00514007) and intermittent (1-3, 5, 7 days or 2 weeks) dosing (NCT00514306). A total of 30 patients received OSI-906 at 10-150 mg qd with one grade 3 hyperglycemia and one grade 3 lipase elevation reported. A total of 25 patients were dosed at 10-450 mg, days 1-3/q2weeks without severe toxicity. Disease stabilization >6 months was observed in one thymic carcinoma, one ACC and two colorectal carcinoma patients receiving OSI-906 in continuous dosing, and one myxoid chondrosarcoma, one ACC and one refractory NSCLC patient receiving OSI-906 40 mg days 1-3 q2weeks. Trends for increases in insulin levels with increasing OSI-906 plasma concentrations were observed (Lindsay et al., 2009 ).
R1507
The safety and pharmacokinetics of weekly and q3weeks administrations of the human anti-IGF-IR IgG1 antibody, R1507 (robatumumab, Roche, Baseln, Switzerland), were explored in a phase I study in patients with advanced solid tumors or lymphomas (NCT00400361) (Rodon et al., 2007) . In total, 21 patients were enrolled in four dose-escalation cohorts (1-16 mg/kg) of weekly R1507. One grade 3 hyperglycemia and one grade 3 CD4-positive lymphopenia were reported. Other adverse events included infection (n ¼ 6) and fatigue (n ¼ 4). Pharmacokinetic analysis estimated a half-life of approximately 8 days. At 1 mg/kg, an average 80% reduction (range, 13-34%) in IGF-IR expression on peripheral blood mononuclear cells was seen on day 8 (n ¼ 7). The weekly dose escalation has been also reported (Leong et al., 2007) . A total of 34 patients were enrolled at three dose levels (1-9 mg/kg). Two adverse events, a cerebrovascular accident and hyperbilirubinemia, were reported at the 9 mg/kg dose. No hyperglycemia was reported; however, glucose tolerance test abnormalities were observed in two of 17 patients at week 7. Half-life was estimated to be 6.2 days at the highest dose. Two objective responses were reported in two patients with Ewing's sarcoma in the 9 mg/kg cohort. Stable disease was reported in another two of eight evaluable Ewing's sarcoma patients. Overall, 10 patients showed stable disease of median duration 18 weeks (range, 12-48).
Sch717454
Sch717454 (19D12, Schering-Plough, Kenilworth, NJ, USA) is a human IgG1 anti-IGF-IR antibody. A phase I, single-dose study at 0.3-20 mg/kg was conducted in 32 healthy volunteers with no adverse events reported up to 8 weeks post dosing (Seraj et al., 2007) . Two phase II clinical trials are currently ongoing to test the efficacy of Sch717454 q2weeks. In the first of these trials, patients X11-year-old with relapsed osteosarcoma that can be treated with surgery, will be randomized to Sch717454 administered at one of two dose levels. Patients will receive Sch717454, have surgery performed and continue to receive treatment with Sch717454. A second cohort of patients with unresectable osteosarcoma or Ewing's sarcoma will receive Sch717454 until disease progression (NCT00617890).
XL228
XL228 (Exelixis, South San Francisco, CA, USA) is a small-molecule tyrosine kinase inhibitor of IGF-IR, Src, fibroblast growth factor receptor and BCR-ABL. A phase I dose escalation of XL228 administered intravenously once or twice weekly was conducted in patients with advanced malignancies (NCT00526838) (Britten et al., 2008) . Data have been reported for four study cohorts (13 patients) receiving XL228 weekly at 0.45-3.6 mg/kg. No DLTs were reported. Pharmacokinetic analysis showed a slightly greater than dose-proportional increase in exposure, with mean terminal halflives ranging from 47 to 55 h, and marked tissue distribution. There were substantial changes in phosphorylation of Src kinase substrates in peripheral blood mononuclear cell after XL228 infusion with up to 78-100% decreases in phosphoepitopes. Rapid and transient increases in plasma glucose and insulin after infusion suggest IGF-IR/IR inhibition. Twelve evaluable patients remained on study at the time of the report and continued to receive XL228 weekly; the longest time on study was experienced by patients with small-cell lung cancer (7 þ cycles) and perirectal leiomyosarcoma (4 þ cycles).
An additional study investigates the safety of XL228 in patients with chronic myeloid leukemia (CML) or Philadelphia-chromosome-positive acute lymphocytic leukemia (ALL; NCT00464113). Dose levels tested include 0.45-10.8 mg/kg once weekly and 3.6 mg/kg twice weekly. A total of 35 patients have received one or Clinical experience with IGF-IR inhibitors A Gualberto and M Pollak more doses of XL228 and seven patients have shown signs of clinical activity: two chronic-phase CML patients showed a complete cytogenetic response, including one patient with a T315I mutation, two patients experienced a major cytogenetic response, including a patient with Philadelphia-chromosomepositive ALL harboring the T315I mutation and three patients with accelerated-phase CML have experienced a return to chronic-phase CML. Serious adverse events that were reported included tumor lysis syndrome, syncope, neutropenia, thrombocytopenia, anemia, fever and infections. DLTs of syncope and hyperglycemia were observed in the 10.8 mg/kg weekly cohort. Inhibition of BCR-ABL (including T315I), IGF-IR and Src kinase was shown by assessment of phosphoprotein epitopes in circulating leukocytes (Cortes et al., 2008) .
Class effects and differentiation Safety
Early results reveal a favorable profile with most adverse events described as mild and/or manageable. Endocrine changes seem to be characteristic of the class and include elevations in circulating IGF-I, GH, insulin and glucose. These have been rarely associated with DLT, although co-administration of anti-diabetic agents has been occasionally necessary to control blood glucose.
Monitering patients for hyperglycemia and/or dehydration is recommended. Mild elevations in blood glucose are seen in about 25% of patients treated with anti-IGF-IR antibodies. There is no evidence to support the simplistic explanation that this is a consequence of cross-reactivity with the IR. These agents were designed to spare it, and there is convincing evidence that this has been achieved. Importantly, although several antibodies target 'hybrid receptors' (comprising a 'half receptor' composed of IR-a and -b chains, complexed with a 'half receptor' composed of IGF-IR-a and -b chains), these are more responsive to IGFs than to insulin, and their role in the regulation of glycemia is controversial (Lammers et al., 1989; Morrow et al., 1994; Belfiore, 2007; Benyoucef et al., 2007) .
Available data are consistent with the more complex mechanism outlined in Figure 1 . Anti-IGF-IR antibodies act systemically on all IGF-IR receptors, including those involved in homeostatic control of GH at the hypothalamic-pituitary axis, causing loss of feedback inhibition of GH secretion. Elevated GH levels stimulate liver IGF-I production, accounting for the observed elevations in circulating IGF-I. Furthermore, elevated GH likely leads to greater liver gluconeogenesis and insulin resistance in muscle, liver and adipose tissue (del Rincon et al., 2007) . This could result in hyperglycemia similar to that seen in acromegalic patients. However, in Clinical experience with IGF-IR inhibitors A Gualberto and M Pollak most patients treated with IGF-IR inhibitors hyperinsulinemia and normoglycemia are observed, suggesting that increased pancreatic secretion of insulin compensates to some extent for the insulin resistance and increased hepatic glucose production. Consequently, severe hyperglycemia is a rare event when IGF-IR antibodies are given as single agents Lacy et al., 2008) . In contrast, up to 20% of severe hyperglycemia is seen in studies in which anti-IGF-IR antibodies are given with chemotherapy that requires pre-medication with steroids, themselves strong hyperglycemic agents . Of note, a combination of CP-751,871 with high-dose steroids in patients with multiple myeloma did not report high frequency or severity of hyperglycemia . This may be due to the fact that when given at high doses in myeloma treatment, steroids significantly interfere with the GH-IGF-I axis at the hypothalamic, pituitary and target organ levels (Hochberg, 2002) , further indicating the complexities of the control systems involved. IgG2 and IgG4 antibodies (CP-751,871, BIIB022) are poor activators of antibody-mediated cytotoxicity and complement fixation and may have less hematological toxicity than those with IgG1 backbone. For example, grade 3 thrombocytopenia was considered dose limiting at 20 mg/kg for AMG-479 in a single-agent study , and with MK0646, grade 3 and 4 thrombocytopenia, respectively, were encountered with a 5 mg/kg weekly regimen (Atzori et al., 2008) and with a 15 mg/kg loading, 5.0 mg/kg q2weeks maintenance regimen (Hidalgo et al., 2008) . Furthermore, grade 3 CD4 þ lymphopenia was observed with R1507 (Rodon et al., 2007) . However, grade 2 lymphopenia has also been seen with CP-751,871 (Olmos et al., 2007) , suggesting that IGF-IR targeting may contribute to hematological toxicity. If future applications involve combinations with aggressive chemotherapy, additive or synergistic hematological toxicity may become an issue. It is also possible that antibody-mediated cytotoxity could contribute to anti-tumor activity and represent an advantage, but there is yet no clinical data supporting that hypothesis.
Pediatric trials have been initiated with five of the anti-IGF-IR monoclonals (Table 2, sarcoma). Longterm therapy would be predicted to result in growth retardation, but that would be of little significance if 'catch-up' growth occurs after completion of treatment. Of note, no growth effects have yet been described in adolescents treated with anti-IGF-IR antibodies (Olmos et al., 2007 (Olmos et al., , 2008 .
Importantly, hypersensitivity reactions have been rare so far for anti-IGF-IR antibodies as a class. Experience with long-term (>1 year) treatment is limited, but might be expected to associate with changes in body composition reminiscent of the syndrome of GH deficiency, including increased adiposity and decreased muscle mass. Long-term IGF-IR inhibition may also have implications in the maintenance of normal physiological functions such atherosclerosis, increased frailty in elderly subjects and bone fractures (Ceda et al., 2005 ). An additional particular concern would be adverse central nervous system effects associated with those drug candidates that accumulate in the brain, as IGF-I signaling has neuroprotective effects (Russo et al., 2005) .
Pharmacokinetics
Target-mediated disposition has been shown for some of the antibodies Lacy et al., 2008; Yin et al., 2008) . Population pharmacokinetics conducted with one of the monoclonals identified body weight as a significant covariate for plasma clearance, whereas age, sex, and albumin or bilirubin concentrations showed no apparent effects . These data support the continuation of body weight-based dosing. As expected, chemotherapy did not affect the pharmacokinetics of anti-IGF-IR monoclonals (Attard et al., 2006; Sarantopoulos et al., 2008; Karp et al., 2009) . It is also noteworthy that the effective half-lives of the anti-IGF-IR antibodies differ from each other. The half-life of CP-751,871 (IgG2) of approximately 20 days seems longer than others (Baserga et al., 2003; Dong et al., 2007) . Halflife estimates of 4 days (Atzori et al., 2008) , 6 days (Leong et al., 2007) , 7-11 days and 9 days (Higano et al., 2007) were reported, respectively, for MK0646, R1507, AMG-479 and A12 (Table 1 ). These differences could be explained in part by antibody backbone, but may also reflect target mediated disposition at low doses (Goodin, 2008) .
Pharmacodynamics IGF-IR downregulation on circulating leukocytes has been shown for several of the antibodies (Table 1) , indicating target modulation, at least in a surrogate tissue. Early results with CTCs suggest similar effects on neoplastic cells (De Bono et al., 2007) . More detailed pharmacodynamic end points on tumor specimens were generated with MK0646 (Atzori et al., 2008) . At 5-20 mg/ kg/week, decreases in IGF-IR, pAKT, pMAPK and pS6 were observed. These findings provide key evidence that despite the fact that many tumors have several receptor kinases upstream of pAKT and pMAPK, targeting the IGF-IR is sufficient to perturb downstream signaling.
Efficacy
To date, encouraging phase II data have been reported with CP-751,871 in NSCLC as summarized above . Well-documented phase I responses were reported with several drug candidates in Ewing's sarcoma and other tumors (Table 1) . Despite these encouraging trends, it is premature to reach formal conclusions. Considerable phase II data should become available within the next 24 months, and phase III studies of CP-751,871 and MK0646 are currently underway.
Gaps in knowledge and future research
Differences between antibodies and tyrosine kinase inhibitors Experience with epidermal growth factor receptor inhibitors shows that it can be difficult to predict Clinical experience with IGF-IR inhibitors A Gualberto and M Pollak differences in efficacy between anti-receptor antibodies and small-molecule inhibitors (Mendelsohn and Baselga, 2006) . Small molecule IGF-IR inhibitors commonly inhibit the IR, the IGF-I receptor, and hybrid receptors, and might be expected to be more effective antineoplastic agents than the antibodies (discussed below). However, they may also have more serious metabolic toxicity ( Table 3 ). Monoclonals that target hybrid receptors, such as Sch717454 or CP-751,871, may block any portion of insulin signaling in cancer cells mediated by those receptors (Cohen et al., 2005; Sachdev et al., 2006; Pollak, 2008a) . Small molecule inhibitors may allow the investigation of drug sequencing and intermittent dosing more conveniently than antibodies. The question of tissue distribution of small-molecule IGF-I/IR kinase inhibitors and their metabolites is also important with respect to both potential toxicity (particularly central nervous system) and efficacy.
Development issues
The biological rationale for IGF-IR-targeting agents suggests the possibility of indication in a wide range of cancers and combination therapies. Although this broad relevance increases enthusiasm for the target, it also presents challenges. A total of 16 tumor types and almost 30 combinations are listed in Table 2 . Preclinical work does suggest that combinations with DNAdamaging cytotoxics, epidermal growth factor receptor family inhibitors, steroid hormone targeting agents mammalian target of rapamycin inhibitors, and radiation may translate to supra-additive effects and deserve prioritization (Benini et al., 2001; Lu et al., 2001; Cohen et al., 2005; Wu et al., 2005 Wu et al., , 2006 Best et al., 2006; O'Reilly et al., 2006; Allen et al., 2007; Barr et al., 2007; Ji et al., 2007; Plymate et al., 2008; Wan et al., 2007; Guix et al., 2008) . Possibilities that intermittent, pulsed or sequenced regimens with cytotoxic agents may or may not have advantages over continuous exposure remain largely unexplored for targeted therapies in general, and IGF-IR inhibitors in particular.
Study design is also challenging. IGF-IR inhibitors can be combined with other agents in ways that may increase their activity or delay the onset of resistance. The first mechanism implies that IGF-IR is constitutively activated in tumors, and thus methods to identify baseline sensitivity to inhibition would be key in future development. The second mechanism is broader and emphasizes the importance of IGF-IR activation in acquired treatment resistance. Delays in progressionfree survival by IGF-IR inhibition will be missed if studies are not powered to evaluate this end point. One interesting study design investigates the reversal of drug resistance. Patients progressing on a therapy are offered its re-administration in combination with an IGF-IR inhibitor. Reversal of drug resistance was anecdotally observed in early studies Karp et al., 2009) , and is currently being tested in several trials of these inhibitors.
Reliable biomarkers predictive of response IGF-IR amplification has been detected in some tumors (Natrajan et al., 2006; Adelaide et al., 2007; Tarn et al., 2008) but does not seem to be a common event as with other receptors (Slamon et al., 2001) . Sensitivity to targeting could correlate with receptor activation, but methods of measurement are not yet perfected. Studies conducted in a series of blood and tumor tissues from patients with NSCLC raised the possibility that receptor and ligand levels may be independent predictors for response to anti-IGF-IR therapy (Gualberto et al., 2008a, b) . These pharmacologically defined groups, receptor or ligand driven, seemed to match two of three tumor differentiation phenotypes: epithelial (differentiated) and epithelial-to-mesenchymal transition (transitional). Patients with tumors belonging to a third phenotype, mesenchymal (undifferentiated), did not seem responsive to anti-IGF-IR therapy (Gualberto et al., 2008a, b; Karp et al., 2009) . The epithelial high IGF-IR expressing phenotype included most squamous cell carcinoma tumors, whereas the transitional liganddriven phenotype was observed in the majority of adenocarcinoma patients. Mesenchymal-like NSCLC was represented by large cell and other undifferentiated tumors that expressed the highest levels of vimentin, and Clinical experience with IGF-IR inhibitors A Gualberto and M Pollak low receptor and ligand levels (Gualberto et al., 2008a, b) . These data suggested that the use of differentiation markers, in addition to receptor and ligand levels, could contribute to the identification of patients susceptible to benefit from anti-IGF-IR therapy, and data emphasized the complexity of IGF-IR biology. Large variations in IGF-IR levels, comparable with that observed in cell lines, have been reported in rhabdomyosarcoma tumor specimens, and pre-clinical experiments showed that receptor number may indeed predict sensitivity to an anti-IGF-IR antibody in rhabdomyosarcoma cell lines (Cao et al., 2008) . In colorectal cancer and other tumors, the role of KRAS and epidermal growth factor receptor status and its relationship to the activity of IGF-IR inhibitors should be object of investigation. Similarly, more research is required to understand the potential effects of p53 and PTEN inactivation on anti-IGF-IR therapy (Hyun et al., 2000; Glait et al., 2006) .
Endocrine deregulation
The hormonal consequences of IGF-IR inhibition could in a sense be regarded as pharmacodynamic evidence of effective targeting. Careful interpretation is needed, as these changes are likely dependent on many variables. For example, the degree to which GH levels rise for a fixed degree of IGF-IR inhibition would be expected to vary with pituitary reserve capacity (for example, elderly versus adolescent patient). Similarly, there is a likely person-to-person variability in the degree of insulin response to GH-induced insulin resistance that is not attributable to drug exposure. The medical consequences of high GH, IGF-I, insulin and glucose levels require careful consideration (Table 4) . None of these changes is desirable, but they seem tolerable. Hyperglycemia is usually controllable with metformin and other agents (Atzori et al., 2008; Karp et al., 2009) . Metformin likely acts to lower hepatic gluconeogenesis, which reduces circulating glucose, and results in secondary decline in insulin without affecting GH or IGF-I levels ). An alternative approach might be the use of GH antagonists, such as pegvisomant (Kopchick et al., 2002) . Importantly, there is no evidence that IGF-I elevation is sufficient to overcome the desired IGF-IR inhibition . This may be due in part to parallel elevations of IGFBPs, which reduce IGF bioactivity Rothenberg et al., 2007; Tolcher et al., 2007; Lacy et al., 2008) . In addition, despite reports of GH receptor expression in human cancers (Gebre-Medhin et al., 2001) , there is no clear evidence that GH has an important direct effect on neoplasia. On the other hand, insulin elevations deserve attention. There is evidence for insulin-receptor expression in human cancers (Law et al., 2008; Cox et al., 2009) and that insulin, acting through its own receptor, can attenuate the effects of IGF-IR targeting (Zhang et al., 2007) . There is also evidence that high insulin secretion is associated with adverse prognosis (Goodwin et al., 2002; Ma et al., 2008; Pollak, 2008a; Wolpin et al., 2009) . However, preliminary reports do not indicate that hyperinsulinemia post anti-IGF-IR treatment translate to worse outcome (Gualberto et al., 2008a) . Likewise, better outcomes are not apparent in patients who develop hyperglycemia . Nevertheless, should hyperinsulinemia or IGF-I elevations be found to be associated with reduced clinical benefit from IGF-IR targeting, there would be clear justification for examining combinations of IGF-IR antibodies with metformin or pegvisomant, as well as exploring in more detail tyrosine kinase inhibitors that target both insulin and IGF-I signaling.
Conclusions
Early clinical trials of IGF-IR-targeting agents have been encouraging enough to justify expanded clinical trial programs. Pharmacodynamic evidence that anti-IGF-IR antibodies reduce receptor signaling is strong. Safety profiles, at least for short-and medium-term treatment durations, are favorable. It is too early to reach conclusions on efficacy. However, rare but impressive instances of major responses in phase I heavily pre-treated patients, together with early evidence of clinical benefit in combination with chemotherapy for lung cancer, have led to expanded development programs. Challenges at this stage include the multitude of potential indications, rational study design and execu- Clinical experience with IGF-IR inhibitors A Gualberto and M Pollak tion, and the need for concurrent evaluation of biomarkers for resistance and sensitivity. Two decades ago, there was speculation that it might be possible to design IGF-IR-targeting agents of utility in cancer treatment (Myal et al., 1984; Pollak et al., 1987; Arteaga et al., 1989) . Recent efforts have shown that molecular entities with the necessary pharmacological properties can indeed be developed, and the intense clinical trial and translational research activity presently underway will soon provide definite data on their value in cancer treatment.
Abbreviations ACC, adrenocortical carcinoma; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukaemia; CTCs, circulating tumor cells; DLT, dose-limiting toxicity; GH, growth hormone; IGFBP-3, insulin-like growth factor-binding protein; IGF-IR, insulin-like growth factor I receptor; IR, insulin receptor; NSCLC, non-small cell lung cancer; q2weeks, every 2 weeks; q3weeks, every 3 weeks; q4weeks, every 4 weeks.
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